Invitrogen Corp. (IVGN)
|
|
|
| 52wk high: | |
| 52wk low: | |
| EPS: | |
| PE: | |
| Dividend: | |
| Yield: | |
| Market Cap: | |
| Exchange: |
Articles on Invitrogen Corp. (IVGN)
19 articles
Filter by:
Latest Articles Most commented on articlesMost frequent authors on IVGN
- Centient Biotech Investor(2)
- Lon Juricic(2)
- SA Editor Judith Levy(2)
- Stockerblog (2)
- Don Dion(1)
Most popular authors
(tracked in watchlists)
- SA Editor Eli Hoffmann(412)
- Andrew Wilkinson(406)
- Market Folly(290)
- Stockerblog (201)
- Mike Havrilla(163)
Most commented on authors
- Stockerblog (9)
- SA Editor Miriam Metzinger(4)
- Andrew Waight(3)
- Mike Havrilla(3)
- Market Folly(2)
- Hedge Fund Tracking: Barry Rosenstein's Jana Partners, Q3 2008
- Cohen's SAC Boosts Stake in Invitrogen to 6.9%
- Biotech Buying Binge About to Begin?
- Will M&A Activity Boost PowerShares Dynamic Biotech & Genome ETF?
- Invitrogen: Stock Will Keep Rising
- Wall Street Breakfast: Must-Know News
- Biomanufacturing: Evaluating Opportunities in the Froth
- Nine Stem Cell Stocks to Add to Your Portfolio
- Loeb's Third Point Issues Latest 13F: Summary of Holdings
- Thursday's Options Report: VIX, Starbucks, Oil Service Holders, Invitrogen, Pozen, Homebuilders ETF, Sohu, Financial Sector ETF
- Investing in Stem Cell Stocks: Growth Industry of the Future?
- Biotech Day In Review: Osiris Stem Cells Treatment Has Unexpected Results
- Color On Invitrogen's Quarter
- Invitrogen Shares Surge on Upside Surprise and Unit Sale
- How Will GE Spend Its Plastics Units Proceeds?
- Top Picks for 2007 from JPMorgan HealthCare Analysts
- Invitrogen Falls Hard on Earnings Miss
- Barron's: Invitrogen May Outperform An Already Strong Industry
- Biotech IPO: Highlights from Rosetta Genomics' F1 Filing
Hedge Fund Jobs
Job Seekers: Search jobs by category, get job alerts by email or live feed, apply online See full list of jobs »
Employers: See all recruitment options, get applications online or by email Post a job »